These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28975392)

  • 1. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
    Dalén J; Svedbom A; Black CM; Kachroo S
    Rheumatol Int; 2017 Dec; 37(12):2049-2058. PubMed ID: 28975392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
    Dalén J; Luttropp K; Svedbom A; Black CM; Kachroo S
    Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.
    Bhoi P; Bessette L; Bell MJ; Tkaczyk C; Nantel F; Maslova K
    BMJ Open; 2017 Sep; 7(9):e015872. PubMed ID: 28928177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.
    Dalén J; Chitkara A; Svedbom A; Olofsson T; Puenpatom A; Black CM; Qureshi ZP
    Adv Ther; 2022 Jun; 39(6):2468-2486. PubMed ID: 34751912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
    Tymms K; Littlejohn G; Griffiths H; de Jager J; Bird P; Joshua F; Nash P; Handel M; McManus H; Butcher BE; Youssef P
    Clin Rheumatol; 2018 Jun; 37(6):1617-1623. PubMed ID: 29667098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.
    Svedbom A; Dalén J; Black CM; Kachroo S
    Patient Prefer Adherence; 2017; 11():95-106. PubMed ID: 28144130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study.
    Carballo N; Garcia-Alzórriz E; Ferrández O; Navarrete-Rouco ME; Durán-Jordà X; Pérez-García C; Monfort J; Cots F; Grau S
    Front Pharmacol; 2021; 12():752879. PubMed ID: 34912219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study.
    Dalén J; Puenpatom A; Luttropp K; Svedbom A; Black CM
    Adv Ther; 2022 Jan; 39(1):244-255. PubMed ID: 34480294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
    Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
    Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions.
    Calip GS; Adimadhyam S; Xing S; Rincon JC; Lee WJ; Anguiano RH
    Semin Arthritis Rheum; 2017 Oct; 47(2):157-164. PubMed ID: 28410817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis.
    Takacs P; Lathia U; Shin J; Nantel F
    Patient Prefer Adherence; 2019; 13():157-163. PubMed ID: 30697037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.
    Borah BJ; Huang X; Zarotsky V; Globe D
    Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD).
    Acar M; Juneja P; Handel M
    Open Access Rheumatol; 2018; 10():151-160. PubMed ID: 30568519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study.
    Alvarez-Madrazo S; Kavanagh K; Siebert S; Semple Y; Godman B; Maciel Almeida A; Acurcio FA; Bennie M
    BMJ Open; 2019 Sep; 9(9):e027059. PubMed ID: 31488467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
    J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.